Literature DB >> 34146727

Liver injury after mRNA-based SARS-CoV-2 vaccination in a liver transplant recipient.

Jérôme Dumortier1.   

Abstract

Entities:  

Keywords:  Covid-19; Liver transplantation; Toxicity; Vaccine

Mesh:

Substances:

Year:  2021        PMID: 34146727      PMCID: PMC8214934          DOI: 10.1016/j.clinre.2021.101743

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


× No keyword cloud information.
Coronavirus disease-2019 (Covid-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is an ongoing global pandemic of major concern, started at the end of 2019. Patients with comorbidities are at high risk of developing severe disease and this includes solid organ transplant recipients [1]. Therefore, Covid-19 vaccine is highly recommended in this population. Neverthless, immunocompromised patients, including solid organ transplant recipients, were not included in the Covid-19 vaccine large trials, especially of Pfizer/BioNTech and Moderna mRNA vaccines, and therefore, safety and efficacy data are lacking in this population. Recently, a significantly reduced immunogenicity of the mRNA SARS-CoV-2 vaccines has been reported [2,3]. Regarding the massive number of patients receiving this vaccination, identification of clinically relevant imputable side-effects of the vaccines is very difficult and therefore a major goal. Herein we report the case of a 46-year-old male, who received the first injection of BNT162b2 mRNA vaccine 123 days after a liver transplantation for alcohol-associated liver disease. At the time of vaccination, the patient was on maintenance immunosuppression therapy with tacrolimus and mycophenolate mofetil, and liver function tests were within normal range. According to systematic biological follow-up, 12 days after vaccination, laboratory findings were as follows: AST 99 U/l (normal: 10–45), ALT 287 U/l (normal: 10–45), alkaline phosphatase (ALP) 270 U/l (normal: 38–120), gamma glutamyl transferase (GGT) 797 U/l (normal: 7–65), total bilirubin 9 mmol/l (normal: 0–20). The patient was totally asymptomatic. Serum HBsAg, anti-HBs, anti-HBc IgM, anti-HAV IgM, anti-HEV IgM, EBV-DNA (PCR), CMV-DNA (PCR), antinuclear antibody, anti-smooth muscle antibody, and anti-liver kidney microsomal antibody were negative. The patient did not consume alcohol on a regular or irregular basis. Other than immunosuppressive treatments included only aspirin. Abdominal Doppler ultrasound was normal. The diagnosis of liver damage related to vaccination was considered and no further investigation was performed, including no liver biopsy. Similarly, no modification of immunosuppressive regimen was done. The second vaccine injection was contra-indicated. Biological evolution was rapidly favourable. One month after initial biological liver injury, laboratory findings were as follows: AST 19 U/l (normal: 10–45), ALT 24 U/l (normal: 10–45), ALP 117 U/l (normal: 38–120), GGT 101 U/l (normal: 7–65), total bilirubin 8 mmol/l (normal: 0–20). We report herein the case of a liver transplant recipient who presented mild liver injury probably due to the first injection of BNT162b2 mRNA vaccine. Evolution was spontaneously favourable. Perturbation of liver function tests was transitory, but detected because of regular systematic (monthly) biological follow-up, less than one year after transplantation. In this context, such diagnosis must be considered together with more usual cause of liver graft injury, such as rejection, in face of significant liver function test abnormalities. Moreover, in the absence of severe liver injury, deleterious manoeuvres (diagnostic or therapeutic) must be ovoid and close biological follow-up performed. The most intuitive expected toxicity of mRNA vaccine (but also all vaccines) is related to immune activation. Therefore, benign and common reported symptoms include soreness, fatigue, myalgia, headache, chills, fever, joint pain, nausea, muscle spasm, sweating, dizziness, flushing, feelings of relief, brain fogging, anorexia, localized swelling, decreased sleep quality, itching, tingling, diarrhoea, nasal stuffiness and palpitations [4]. The flip side of the possibly beneficial adjuvant inflammation, however, is potential toxicity of the mRNA vaccines. And remember that this type of vaccine has also been evaluated as an anti-cancer treatment. With the Covid-19 vaccines, we are using this new type of vaccine for the first time on a very large scale. From preliminary animal and human studies on previous mRNA vaccines, the clinical adverse effects have included myopathy (caused by mitochondrial toxicity), lipodystrophy, lactic acidosis, pancreatitis, liver steatosis, and nerve damage and some were severe [5]. A better understanding of the toxicity of Covid-19 vaccines, particularly mRNA vaccines, can only be based on comprehensive reporting of even apparently mild cases. These cases will be more easily identified in special populations under close clinical and biological surveillance, such as transplant patients, as reported in our patient. Perhaps these patients are also at greater risk.
  8 in total

1.  Safety analysis of COVID-19 vaccines in liver transplant recipients: a two-center study.

Authors:  Rui Tang; Chao Li; Guangdong Wu; Xuan Tong; Lihan Yu; Huayuan Hao; Rui Liao; Yucheng Hou; Jun Li; Wenping Zhao; Tieyan Fan; Leida Zhang; Qian Lu
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

Review 2.  Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update.

Authors:  Pimsiri Sripongpun; Nawamin Pinpathomrat; Jackrapong Bruminhent; Apichat Kaewdech
Journal:  Front Med (Lausanne)       Date:  2022-06-22

3.  Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model.

Authors:  Can Li; Yanxia Chen; Yan Zhao; David Christopher Lung; Zhanhong Ye; Wenchen Song; Fei-Fei Liu; Jian-Piao Cai; Wan-Man Wong; Cyril Chik-Yan Yip; Jasper Fuk-Woo Chan; Kelvin Kai-Wang To; Siddharth Sridhar; Ivan Fan-Ngai Hung; Hin Chu; Kin-Hang Kok; Dong-Yan Jin; Anna Jinxia Zhang; Kwok-Yung Yuen
Journal:  Clin Infect Dis       Date:  2022-06-10       Impact factor: 20.999

4.  Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients.

Authors:  Lea Timmermann; Brigitta Globke; Georg Lurje; Moritz Schmelzle; Wenzel Schöning; Robert Öllinger; Johann Pratschke; Bettina Eberspächer; Christian Drosten; Jörg Hofmann; Dennis Eurich
Journal:  Vaccines (Basel)       Date:  2021-12-01

5.  Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs.

Authors:  Stephanie Seneff; Greg Nigh; Anthony M Kyriakopoulos; Peter A McCullough
Journal:  Food Chem Toxicol       Date:  2022-04-15       Impact factor: 5.572

Review 6.  Current Evidence in SARS-CoV-2 mRNA Vaccines and Post-Vaccination Adverse Reports: Knowns and Unknowns.

Authors:  Dimitra S Mouliou; Efthimios Dardiotis
Journal:  Diagnostics (Basel)       Date:  2022-06-26

7.  Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents.

Authors:  Palittiya Sintusek; Supranee Buranapraditkun; Siriporn Khunsri; Varattaya Saengchaisukhonkit; Preeyaporn Vichaiwattana; Donchida Srimuan; Thanunrat Thongmee; Yong Poovorawan
Journal:  Vaccines (Basel)       Date:  2022-08-16

8.  Association of COVID-19 vaccination before conception with maternal liver function during early pregnancy: a cohort study of 7745 Chinese pregnant women.

Authors:  Yan Zhao; Yongbo Zhao; Mengyuan Li; Yicheng Zhou; Yijun Zhang; Xin Su; Ziyi Zhang; Liping Jin
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.